BioCryst Pharmaceuticals, Inc. (BCRX) Earnings

Management highlights

- Commercial Launch Updates: Orlodeo oral pellets for pediatric HAE patients began shipping in Q2 2026, with 47 prescriptions filled by July 31, 2026, well ahead of full-year expectations. Half of these prescriptions have completed prior authorization with a strong approval rate, and payer reimbursement for adult Orlodeo improved to 84% at quarter-end, up from 83% year-over-year. Biochrist transitioned to CareMed as the new sole-source specialty pharmacy for all Orlodeo shipments to support scaled growth, with the 12+ age patient group transitioning during Q3 2026. New adult Orlodeo prescription volume remained consistent with historical trends, and new prescribers were added at the historical average of ~60 new clinicians per month, slightly above average in Q2. Patient and physician preference and satisfaction for Orlodeo increased year-over-year. - Pipeline & R&D Strategy Updates: Biochrist completed ahead of schedule enrollment for the Alpha Orbit pivotal Phase 3 trial of Nevenibat (Navanibhat), an investigational long-acting injectable HAE prophylaxis; this is the largest blinded HAE trial ever conducted. Top-line data is expected in Q3 2027, with the study remaining blinded to collect 12 months of safety and efficacy data as agreed with the FDA. The Phase 1b proof-of-concept trial for BCX17725 for Netherton syndrome (a rare condition with no approved therapies) is enrolling well, with data expected by the end of 2026. Management decided to wind down all internal drug discovery programs and close the Birmingham research facility by the end of 2026 to shift to an external innovation model for pipeline expansion, which will reduce long-term operating costs with no impact on ongoing clinical programs. Biochrist completed the integration of acquired Astrea Therapeutics during the quarter. - Financial Position: Biochrist ended Q2 2026 with over $350 million in cash, cash equivalents, and investments, and generated positive operating cash flow even excluding the Navanibhat license upfront proceeds. Operating profitability remains strong, supporting the company's self-funded business development and pipeline strategy.

Guidance

- Full-year 2026 total revenue guidance was raised to $690-$715 million, up from prior guidance, driven by the upfront payment from the Navanibhat European license agreement. - Full-year 2026 Orlodeo revenue guidance was maintained at $625-$645 million, as long-term growth trends remain intact despite the delayed pediatric launch. - Full-year 2026 non-GAAP operating cost guidance was lowered from the prior range of $450-$470 million to $420-$440 million, reflecting cost savings from the wind-down of internal discovery programs and Birmingham facility closure. - Management expects operating costs to continue declining after 2026, following completion of facility closure and internal program wind-down, and as Navanibhat and BCX17725 development activities mature. Biochrist remains committed to maintaining profitable growth and positive cash flow even after adding new business development assets.

Segment performance

Biochrist recorded total Q2 2026 revenue of $213.9 million, representing a 45% year-over-year increase on a comparable basis (excluding the former European divestiture). The Orlodeo therapeutic segment contributed $158.2 million in revenue, accounting for approximately 74% of total Q2 revenue, and grew 10% year-over-year. A one-time $55.7 million upfront payment from the Navanibhat European License Agreement with Neopharm at Gentilly made up the remaining ~26% of total Q2 revenue. Non-GAAP operating profit for the quarter was $113.2 million, with G&A and sales and marketing expenses remaining relatively flat year-over-year, while R&D expenses increased due to ongoing Phase 3 activities for Navanibhat.

Risks & headwinds

- Any transition to a new sole-source specialty pharmacy carries potential near-term operational risks that could disrupt patient access during the transition period, though management expects no long-term impact on Orlodeo performance. - New competing HAE prophylactic products have entered the market, creating competitive pressure that could lead to higher patient churn for Orlodeo, even though management has not observed material impact to date. - Netherton syndrome is a rare, naturally variable disease with waxing and waning symptoms, which complicates interpretation of clinical trial efficacy data and may increase the risk of an underwhelming trial result even for an effective investigational therapy. - Early pediatric Orlodeo prescription demand is positive, but adoption and long-term retention in the pediatric population remain uncertain, and it will take multiple quarters to establish real-world performance trends. Reimbursement rates for pediatric Orlodeo have not yet been fully confirmed, though early signals are positive.

Analyst Q&A

• Q: An analyst asked whether new competitor injectable HAE products are increasing patient churn for Orlodeo, and provided an update on BCX17725 (Netherton syndrome) enrollment progress. /

  A: Management stated new competing injectables primarily draw patients from older existing injectable products, not Orlodeo. Orlodeo patient retention remains consistent with historical trends, and management remains positive about long-term Orlodeo growth. For BCX17725, enrollment is on track to complete this year, the drug has been well tolerated to date, and full proof-of-concept data will be available by the end of 2026.

• Q: An analyst asked for context on Orlodeo Q2 2026 volume growth, given the 9% list price increase and improved 84% payer reimbursement rate. /

  A: Management confirmed that Q2 2026 Orlodeo revenue growth was split evenly between volume growth and combined pricing/reimbursement improvements, consistent with prior expectations for net price impact from the list price increase.

• Q: An analyst asked to clarify Biochrist's business development priorities under the new external innovation strategy, and for operating expense outlook for 2027 under different BCX17725 outcomes. /

  A: Management will prioritize high-quality mid-stage clinical rare disease assets that leverage Biochrist's existing commercial and development strengths, and will avoid large, balance-sheet-stressing acquisitions. Biochrist is cash-generating and self-sufficient, so it will not need large capital raises to fund new deals. For 2027, operating costs will decline further as legacy internal R&D costs are eliminated, and existing clinical program costs will decrease as they mature. Biochrist remains committed to profitable growth regardless of new pipeline additions.

• Q: An analyst asked what is driving the consistent new patient prescription momentum for Orlodeo, and whether new demand is only from pediatric patients. /

  A: Management confirmed new adult prescription demand remained consistent with historical trends, matching expectations, while the early strong pediatric prescription demand is upside on top of the steady adult business. Long-term pediatric adoption trends will become clear over multiple quarters.